Cardiology Letters 2019, 28(4):184-187

Proprotein convertase subtilisin/kexin type 9 inhibitors in the treatment of a patient with dyslipidemia and myopathy

Nesvadba M^{1, 2}, Cmorej PCh^{3, 4}, Vostrý M³, Peřan D^{5, 6}, Bureš P⁴, Kohlová A^{3, 7}

¹ Ordinace praktického lékaře v Turnově, Česká republika

² Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety v Bratislave, Slovenská republika

³ Fakulty zdravotnických studií, Univerzita Jana Evangelisty Purkyně v Ústí nad Labem, Česká republika

⁴ Zdravotnické záchranné služby Ústeckého kraje, p. o., Česká republika

⁵ Zdravotnické záchranné služby hl. m. Prahy, Praha, Česká republika

⁶ Kabinetu veřejného zdravotnictví, 3. lékařská fakulta UK v Praze, Praha, Česká republika

⁷ Ústav ošetrovateľstva, Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Slovenská republika

We present a 46-year-old patient with mixed dyslipidaemia and muscle pain. This patient, despite his low age, had a myocardial infarction and was subsequently indicated for the treatment of dyslipidaemia in secondary prevention. Significant elevation of creatine kinase occurred at the beginning of statin therapy. For this reason statins were discontinued and the patient was referred to a lipidology clinic. Ezetimibe and fenofibrate were used in the clinic. These drugs did not achieve the LDL-cholesterol target and therefore the proprotein convertase inhibitor subtilisin / kexin type 9 (PCSK9), with excellent tolerance and desirable reduction in LDL-cholesterol was chosen. Ref. 14, on-line full text (Free, PDF) www.cardiologyletters.sks.sk

Keywords: mixed dyslipidaemia; inhibitor of PCSK9; myopathy; evolokumab

Published: April 1, 2019  Show citation